Filter results by document type and/or working area to find what you're searching for.
XbarM is a real-time analyser monitoring available on Sysmex 5-part differential analysers, XN-L Series and XN-Series, which uses patient samples measured during the daily lab routine. Unlike internal quality control with stabilised material, the XbarM offers a long-term and continuous control process over the entire working day. Using the XbarM, the functionality of all connected reagents, e.g. before and after reagent replacement is monitored in an optimal manner as well as the analyser itself, e.g. before and after calibration or sensitivity adjustment. It does not require any extra input from the user because, once activated and set up correctly, it runs automatically in the background. This SEED article describes the different types of monitored parameters, recommended XbarM settings as well as tips for troubleshooting.
Myelodysplastic syndromes (MDS) often go unnoticed when only a complete blood count is performed on the patient. Sysmex X-Class analysers can measure the granularity of leukocytes which is often reduced in MDS. NEUT-X, the measure of neutrophil granularity, is an excellent tool to filter samples suspected of MDS in anaemic patients.
By combining the WDF and WPC channels both the sensitivity and specificity for detecting reactive and malignant cells is optimised. The measurement technology of XN-Series analysers detects the white blood cell functionality and the novel ‘Extended Inflammation Parameters’ let you quantify activated lymphocytes and neutrophils, and the results can be applied once a malignancy has been excluded.
Determining the aetiology of thrombocytopenia is of major importance. The immature platelet fraction (IPF) can help you promptly differentiate between ineffective bone marrow production and increased destruction or consumption of platelets. Find out more about the use of this parameter here.
The treatment of immune thrombocytopenia (ITP) can be challenging. The immature platelet count (IPF#) can help, making it easier to monitor the efficacy of the different treatment mechanisms and assessing bleeding risks. This white paper explains how.